BioMarin (Phase III PARP) Overview
- Status
- Acquired/Merged
- Latest Deal Type
- Asset Purch.
- Financing Rounds
- 1
BioMarin (Phase III PARP) General Information
Description
Provider of drugs for the treatment of breast cancer. The company specializes in orally-available poly ADP ribose polymerase (PARP) inhibitor currently in a Phase 3 study for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Drug Discovery
Acquirer
Primary Office
- 770 Lindaro Street
- San Rafael, CA 94901
- United States
BioMarin (Phase III PARP) Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore BioMarin (Phase III PARP)‘s full profile, request access.
Request a free trialBioMarin (Phase III PARP) Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore BioMarin (Phase III PARP)‘s full profile, request access.
Request a free trial